TNL Mediagene (NASDAQ: TNMG) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of next-generation gene therapies targeting rare and underserved genetic disorders. Established in 2005 as a spin-out from leading academic research institutions, the company has built a proprietary gene-editing platform that enables precise modification of disease-causing genes. TNL’s platform leverages advanced viral and non-viral vector technologies to deliver therapeutic payloads to target tissues with high specificity and sustained expression.
The company’s pipeline includes multiple product candidates addressing neuromuscular disorders, inherited metabolic diseases and blood-clotting disorders. Lead programs encompass AAV-based approaches for spinal muscular atrophy, CRISPR-enabled treatments for hemophilia A and B, and lipid nanoparticle platforms for lysosomal storage diseases. In addition to its therapeutic efforts, TNL Mediagene offers contract research and development services to academic partners and pharmaceutical sponsors, supporting target validation, preclinical evaluation and manufacturing process optimization.
TNL Mediagene maintains research and development facilities in Cambridge, Massachusetts, and Munich, Germany, complemented by a strategic partnership network spanning Asia and North America. Collaborative agreements with academic medical centers, biotechnology innovators and global contract manufacturing organizations underpin the company’s efforts to accelerate clinical development and scale up production. These alliances ensure access to specialized expertise, cutting-edge laboratory infrastructure and regional regulatory guidance.
Under the leadership of Chief Executive Officer Dr. Sarah Tan, the company is governed by a management team with deep experience in gene therapy, drug development and regulatory affairs. Dr. Tan is supported by a board of directors comprising industry veterans and scientific advisors who have guided multiple biologics to market. TNL Mediagene remains committed to advancing transformative treatments for patients with limited therapeutic options and driving long-term value through innovation in genetic medicine.
AI Generated. May Contain Errors.
